BECTON DICKINSON and CO

BDX’s steady 6.2% gain, above its 200‑day SMA, shows why investors are bullish on Becton Dickinson’s precision‑medicine tech—now’s the time to consider BDX.

BDX’s slight slide highlights a market test of Becton Dickinson’s growth narrative—innovation vs. valuation, with investors eyeing a potential correction.